期刊文献+

过表达乙酰肝素酶对胆囊癌细胞增殖及PI3K/AKT信号通路的影响 被引量:2

Effect of overexpression of heparanase on proliferation of gallbladder cancer cells and PI3K/AKT signaling pathway
下载PDF
导出
摘要 目的探讨过表达乙酰肝素酶(HPSE)对胆囊癌细胞系GBC-SD细胞增殖及磷脂酰肌醇3-激酶/蛋白质丝氨酸苏氨酸激酶(PI3K/AKT)信号通路的影响。方法构建HPSE真核表达载体,然后获得转基因过表达HPSE的胆囊癌细胞株GBD-SD。通过实时荧光定量聚合酶链反应(qRT-PCR)和Western blot分析GBC-SD和GBD-SD中HPSE mRNA和蛋白表达。通过集落形成实验、MTT来评估各组细胞的增殖情况。采用Western blot分析PI3K/AKT信号通路相关蛋白(p-PI3K、PI3K、p-AKT和AKT)的水平。结果成功转染后的GBD-SD中HPSE mRNA水平和蛋白水平升高,差异有统计学意义(P<0.01)。与正常表达HPSE的GBC-SD相比,过表达HPSE的GBD-SD细胞光密度(OD)值和集落形成能力提高,差异有统计学意义(P<0.05)。Western blot检测结果显示,与GBC-SD细胞相比,过表达HPSE的GBD-SD组细胞p-AKT、p-PI3K蛋白表达水平、p-AKT/AKT值和p-PI3K/PI3K值增加,差异有统计学意义(P<0.01),而总AKT和总PI3K蛋白表达水平无明显变化。GBC-SD细胞经PI3K/AKT通路特异性抑制剂LY294002处理2 d后,其增殖能力和p-AKT/AKT值降低,差异有统计学意义(P<0.01)。结论过表达HPSE能够促进GBC-SD细胞的增殖,这一效应可能与PI3K/AKT信号通路有关。 Objective To explore the effect of overexpression of heparanase(HPSE) on the proliferation of gallbladder cancer cell line GBC-SD and the phosphatidylinositol 3-kinase/protein serine-threonine kinase(PI3 K/AKT) signaling pathway. Methods The HPSE eukaryotic expression vector was constructed, and then the gallbladder cancer cell line GBD-SD with transgenic overexpression of HPSE was obtained. The mRNA and protein expression of HPSE in GBC-SD and GBD-SD were analyzed by quantitative real-time polymerase chain reaction(qRT-PCR) and western blot. The proliferation of cells in each group was assessed by colony formation assay and MTT. The protein levels of PI3 K/AKT signaling pathway related proteins(p-PI3 K, PI3 K, p-AKT and AKT) were analyzed by western blot. Results The mRNA and protein levels of HPSE in GBD-SD after successful transfection were significantly increased(P<0.01). Compared to GBC-SD with normal expression of HPSE, the optical density(OD) value and colony formation ability of GBD-SD cells with overexpression of heparanase were significantly increased(P<0.05). The results of western blot showed that compared with GBC-SD cells, the expression levels of p-AKT, p-PI3 K protein, p-AKT/AKT value and p-PI3 K/PI3 K value in GBD-SD cells with overexpression of HPSE were increased significantly(P<0.01), but the expression levels of total AKT and total PI3 K protein did not change obviously. After 2 days of treatment with specific inhibitor LY294002 for PI3 K/AKT pathway,the proliferation ability and p-AKT/AKT value of GBC-SD cells were significantly decreased( P < 0. 01). Conclusion Overexpression of HPSE can promote the proliferation of GBC-SD cells,which may be related to the PI3 K/AKT signaling pathway.
作者 闻波 刘子祥 张子艳 陈佳伟 王郑林 周少波 WEN Bo;LIU Zixiang;ZHANG Ziyan;CHEN Jiawei;WANG Zhenglin;ZHOU Shaobo(Department of General Surgery,the Second Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,233000)
出处 《实用临床医药杂志》 CAS 2022年第2期56-61,共6页 Journal of Clinical Medicine in Practice
基金 安徽省高等学校自然科学研究项目(KJ2020A0564) 2021年度安徽省卫生健康委科研项目(AHWJ2021a012) 蚌埠医学院自然科学重点项目(BYKY2019130ZD)
关键词 胆囊癌 乙酰肝素酶 细胞增殖 磷脂酰肌醇3-激酶 蛋白质丝氨酸苏氨酸激酶 信号通路 gallbladder cancer heparanase cell proliferation phosphatidylinositol 3-kinase protein serine-threonine kinases signaling pathway
  • 相关文献

参考文献4

二级参考文献12

  • 1Josep M Llovet,Andrew Burroughs,Jordi Bruix.Hepatocellular carcinoma[J]. The Lancet . 2003 (9399)
  • 2Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 3Sheung Tat Fan,Chung Mau Lo,Ronnie T. P. Poon,Chun Yeung,Chi Leung Liu,Wai Key Yuen,Chi Ming Lam,Kelvin K. C. Ng,See Ching Chan.Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience[J].Annals of Surgery.2011(4)
  • 4Roberto Gedaly,Paul Angulo,Jonathan Hundley,Michael F. Daily,Changguo Chen,B. Mark Evers.PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation[J].Journal of Surgical Research.2012(2)
  • 5Luca Faloppi,Mario Scartozzi,Elena Maccaroni,Marzia Di Pietro Paolo,Rossana Berardi,Michela Del Prete,Stefano Cascinu.Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options[J].Cancer Treatment Reviews.2010(3)
  • 6Chun-Jen Liu,Po-Huang Lee,Deng-Yn Lin,Cheng-Chung Wu,Long-Bin Jeng,Pin-Wen Lin,King-Tong Mok,Wei-Chen Lee,Hong-Zen Yeh,Ming-Chih Ho,Sheng-Shun Yang,Ching-Chih Lee,Ming-Chin Yu,Rey-Heng Hu,Cheng-Yuan Peng,Kuan-Lang Lai,Stanley Shi-Chung Chang,Pei-Jer Chen.Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage[J].Journal of Hepatology.2009(5)
  • 7Alejandro Forner,Sasan Roayaie.Clinical research in hepatocellular carcinoma: Study design and endpoints[J].Journal of Hepatology.2009(5)
  • 8Hiroshi Ishii,Junji Yamamoto,Takaaki Ikari.Adjuvant treatments for resectable hepatocellular carcinoma[J].Journal of Hepato - Biliary - Pancreatic Surgery.2008(5)
  • 9Jonathan D Schwartz,Myron Schwartz,John Mandeli,Max Sung.Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials[J].Lancet Oncology.2002(10)
  • 10Ronnie Tung-Ping Poon,Sheung-Tat Fan,John Wong.Risk Factors, Prevention, and Management of Postoperative Recurrence After Resection of Hepatocellular Carcinoma[J].Annals of Surgery.2000(1)

共引文献23

同被引文献19

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部